QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text PDF For Our Patients Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berger, W. E Articles by Staudinger, H. W Search for Related Content PubMed PubMed Citation Articles by Berger, W. E Articles by Staudinger, H. W

ALLERGY

Mometasone Furoate Improves Congestion in Patients with Moderate-to-Severe Seasonal Allergic Rhinitis

¹ Clinical Professor, Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, CA
² Assistant Professor, Department of Pediatrics, University of Illinois College of Medicine, Peoria, IL
³ Vice President of Allergy/Respiratory Disease, Schering-Plough Corp., Kenilworth, NJ

Reprints: Dr. Berger, Allergy and Asthma Associates, 27800 Medical Center Rd., Ste. 244, Mission Viejo, CA 92691-6410, fax 949/365-0117, weberger{at}uci.edu

BACKGROUND: A recent survey estimated that 85% of patients with allergic rhinitis experience nasal congestion. This symptom considerably impacts quality of life.

OBJECTIVE: To evaluate the effectiveness of mometasone furoate nasal spray (MFNS) in subjects with seasonal allergic rhinitis (SAR) experiencing moderate-to-severe nasal congestion.

METHODS: Data were obtained from 4 randomized, double-blind, placebo-controlled studies of MFNS 200 µg once daily in patients with SAR. Subject-evaluated nasal congestion score data (score range 0-3) from subjects receiving MFNS or placebo were analyzed as a pool and grouped according to baseline score (all pts. with scores >2.5, >2.75, or 3.0). The 2-week average change in score from baseline was analyzed.

RESULTS: Significant improvements in mean nasal congestion score were seen with MFNS (n = 490) versus placebo (n = 492; p < 0.001). Overall, there was a 27% improvement in this score in patients receiving MFNS versus 13% with placebo. MFNS produced significant reductions in the nasal congestion score compared with placebo, even in patients with the most severe baseline congestion (0.98 vs 0.52; p < 0.001). Improvements in scores from baseline of 32%, 33%, and 34% were seen with MFNS versus 22%, 21%, and 18% with placebo (for baseline scores of >2.5, >2.75, or 3.0, respectively), confirming the effectiveness of MFNS regardless of congestion severity. This represents an improvement approximating a decrease from severe to moderate congestion or from moderate-to-severe to mild-to-moderate congestion. MFNS was well tolerated.

CONCLUSIONS: MFNS 200 µg once daily produces statistically significant improvements in nasal congestion score compared with placebo, alleviating severe congestion in patients with moderate-to-severe SAR.

Key Words: allergic rhinitis, congestion, corticosteroid, mometasone furoate

Published Online, November 8, 2005. www.theannals.com, DOI 10.1345/aph.1G202

This article has been cited by other articles:

				H. Li, W. Wen, L. Cheng, J. Shi, H. Jiang, Y. Oh, and G. Xu Expression of Chloride Channel Protein CLC-3 in Patients With Allergic Rhinitis: Effect of Topical Corticosteroid Treatment Arch Otolaryngol Head Neck Surg, March 1, 2008; 134(3): 301 - 305. [Abstract] [Full Text] [PDF]